Recently, molecular targeted therapy has greatly improved the clinical course of patients with nonsmall cell lung cancer (NSCLC) with common driver mutations, including mutations in the epidermal growth factor receptor (EGFR) and translocation in the anaplastic lymphoma kinase (ALK) genes 2. This evidence concerns the gene ALK and non-small cell lung carcinoma.